Catalog No.
YHE83701
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Lys2308-His2537
Predicted molecular weight
28.51 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P51587
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
BRCA2, FANCD1, FACD, Fanconi anemia group D1 protein, Breast cancer type 2 susceptibility protein
Unexpected Twin Pregnancy in a BRCA2-Positive Breast Cancer Patient with Post-Chemotherapy Amenorrhea: A Case Report and Call for Comprehensive Contraceptive Counseling., PMID:40510334
RNA transcripts regulate G-quadruplex landscapes through G-loop formation., PMID:40504899
Hereditary breast cancer beyond BRCA: clinicopathological characteristics and long-term outcomes., PMID:40504267
KIF2C condensation concentrates PLK1 and phosphorylated BRCA2 on kinetochore microtubules in mitosis., PMID:40498077
In silico screening, ADMET analysis and computational simulation studies on Garcinia indica Choisy phytoconstituents as prospective antibreast cancer agents: a critical appraisal of the neglected plant., PMID:40487787
Comprehensive review of male breast cancer: Understanding a rare condition., PMID:40486874
Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer-Specific Polygenic Scores., PMID:40462315
BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function., PMID:40460119
Quality of life after risk reducing mastectomy in a Portuguese cohort of BRCA pathogenic/likely pathogenic variant carriers., PMID:40445415
BRCA2 C-terminal clamp restructures RAD51 dimers to bind B-DNA for replication fork stability., PMID:40441151
Bioprospecting potential genetic biomarkers of gallbladder cancer., PMID:40439781
Different Mechanisms in Doxorubicin-Induced Neurotoxicity: Impact of BRCA Mutations., PMID:40429877
Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment., PMID:40427638
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers., PMID:40427518
Treatment Patterns, Clinical Outcomes and Quality of Life in BRCA1/2-Associated Breast Cancer Patients: A Retrospective Analysis., PMID:40422528
Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage., PMID:40422251
5'UTR gene regions in germline DNA sequencing panels: lessons from the analysis of breast and ovarian cancer patients of Tatar and Bashkir ethnic origin., PMID:40419811
[Association analysis on BRCA gene functional domain mutations and prognosis in patients with ovarian epithelial carcinoma and fallopian tube carcinoma]., PMID:40419351
Detection rates of multigene panel and exome testing in patients with previous negative BRCA1/2 results., PMID:40418377
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification., PMID:40413188
Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study., PMID:40408052
Unraveling SET: Exploring ovarian high-grade serous carcinoma and its BRCA1/2 immunoexpression., PMID:40405589
Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study., PMID:40405286
Identifying the germline variation spectrum and predisposition genes in Chinese ovarian cancer using whole exome sequencing., PMID:40405108
Next-generation sequencing identifies the presence of protein phosphatase 1D, PPM1D, as a potential biomarker of resistance to PARP inhibition in metastatic castration-resistant prostate cancer., PMID:40400994
Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE., PMID:40399999
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation., PMID:40397306
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients., PMID:40392478
Contralateral breast cancer in patients carrying mutations in the BRCA1∕2 gene., PMID:40384197
A Multi-Level Analysis of Barriers and Promoting Factors to Cascade Screening Uptake Among Male Relatives of BRCA1/2 Carriers: A Qualitative Study., PMID:40374330
Hotspot BRCA1/2 Mutations in Tumors With Microsatellite Instability Suggest Passenger Mutation Status and Evaluation of Therapeutic Options., PMID:40373258
Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer., PMID:40370063
Long-Term Oncologic Outcome of Breast-Conserving Treatment in Patients With Breast Cancer With BRCA Variants., PMID:40366658
CA125 Serum Levels in BRCA1/BRCA2 Pathogenic Sequence Variant Carriers as an Ovarian Cancer Screening Tool: A Longitudinal Study., PMID:40365969
Factors affecting the implementation of cascade testing of patients with BRCA1 or BRCA2 pathogenic germline variants in Japan., PMID:40361302
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial., PMID:40360463
Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status., PMID:40359671
Clinical aspect of male breast cancer: a burgeoning and unaddressed issue., PMID:40358767
Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records., PMID:40347974
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study., PMID:40347973
Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors., PMID:40344964
Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancreatic cancer: The arguments for and against., PMID:40339999
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants., PMID:40338220
Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells., PMID:40327605
Distinct roles of the two BRCA2 DNA-binding domains in DNA damage repair and replication fork preservation., PMID:40323719
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data., PMID:40323485
Gender-affirming chest surgery decisions in response to hypothetical BRCA1/2 genetic testing., PMID:40317815
BRCA1/2 methylation and expression dynamics in hereditary breast and ovarian cancer: insights from gene, protein, and TCGA analysis., PMID:40307595
Exploring the Potential of Homologous Recombination Protein PALB2 in Synthetic Lethal Combinations., PMID:40300769
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial., PMID:40300425
For research use only. Not for human or drug use.
